Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2
Lisa H. Tostanoski, Lisa E. Gralinski, David R. Martinez, Alexandra Schaefer, Shant H. Mahrokhian, Zhenfeng Li, Felix Nampanya, Huahua Wan, Jingyou Yu, Aiquan Chang, Jinyan Liu, Katherine McMahan, John D. Ventura, Kenneth H. Dinnon, Sarah R. Leist, Ralph S. Baric, Dan H. Barouch
Abstract
We have developed a series of SARS-CoV-2 vaccines using rhesus adenovirus serotype 52 (RhAd52) vectors, which exhibit a lower seroprevalence than human and chimpanzee vectors, supporting their development as novel vaccine vectors or as an alternative adenovirus (Ad) vector for boosting. We sought to test these vaccines using a recently reported mouse-adapted SARS-CoV-2 (MA10) virus to (i) evaluate the protective efficacy of RhAd52 vaccines and (ii) further characterize this mouse-adapted challenge model and probe immune correlates of protection. We demonstrate that RhAd52 vaccines elicit robust SARS-CoV-2-specific antibody responses and protect against clinical disease and viral replication in the lungs. Further, binding and neutralizing antibody titers correlated with protective efficacy. These data validate the MA10 mouse model as a useful tool to screen and study novel vaccine candidates, as well as the development of RhAd52 vaccines for COVID-19.